Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SKB315 combination therapy in unresectable locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma
CTR20262006Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lucansatuzumab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Jun 2026; status: active.
02
Drugs
lucansatuzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20262006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262006.